BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11581260)

  • 1. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
    Coxon FP; Helfrich MH; Larijani B; Muzylak M; Dunford JE; Marshall D; McKinnon AD; Nesbitt SA; Horton MA; Seabra MC; Ebetino FH; Rogers MJ
    J Biol Chem; 2001 Dec; 276(51):48213-22. PubMed ID: 11581260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
    Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates.
    Coxon FP; Taylor A; Stewart CA; Baron R; Seabra MC; Ebetino FH; Rogers MJ
    Bone; 2011 Jul; 49(1):111-21. PubMed ID: 21419243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
    Roelofs AJ; Hulley PA; Meijer A; Ebetino FH; Russell RG; Shipman CM
    Int J Cancer; 2006 Sep; 119(6):1254-61. PubMed ID: 16619218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
    McKenna CE; Kashemirov BA; Błazewska KM; Mallard-Favier I; Stewart CA; Rojas J; Lundy MW; Ebetino FH; Baron RA; Dunford JE; Kirsten ML; Seabra MC; Bala JL; Marma MS; Rogers MJ; Coxon FP
    J Med Chem; 2010 May; 53(9):3454-64. PubMed ID: 20394422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
    Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
    Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
    Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton.
    Ali N; Jurczyluk J; Shay G; Tnimov Z; Alexandrov K; Munoz MA; Skinner OP; Pavlos NJ; Rogers MJ
    Small GTPases; 2015 Oct; 6(4):202-11. PubMed ID: 26399387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K; Dunford JE; Ebetino FH; Rogers MJ
    Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
    Marma MS; Xia Z; Stewart C; Coxon F; Dunford JE; Baron R; Kashemirov BA; Ebetino FH; Triffitt JT; Russell RG; McKenna CE
    J Med Chem; 2007 Nov; 50(24):5967-75. PubMed ID: 17975902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase.
    Baron RA; Tavaré R; Figueiredo AC; Błazewska KM; Kashemirov BA; McKenna CE; Ebetino FH; Taylor A; Rogers MJ; Coxon FP; Seabra MC
    J Biol Chem; 2009 Mar; 284(11):6861-8. PubMed ID: 19074143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.